Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ABT 
Abbott Laboratories (ABT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ABT (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
28 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $142.48
1 Year Target Price $142.48
| 12 | Strong Buy |
| 7 | Buy |
| 9 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.05% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 228.80B USD | Price to earnings Ratio 16.49 | 1Y Target Price 142.48 |
Price to earnings Ratio 16.49 | 1Y Target Price 142.48 | ||
Volume (30-day avg) 28 | Beta 0.7 | 52 Weeks Range 109.57 - 139.95 | Updated Date 08/27/2025 |
52 Weeks Range 109.57 - 139.95 | Updated Date 08/27/2025 | ||
Dividends yield (FY) 1.76% | Basic EPS (TTM) 7.97 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 32.43% | Operating Margin (TTM) 19.73% |
Management Effectiveness
Return on Assets (TTM) 6.62% | Return on Equity (TTM) 30.93% |
Valuation
Trailing PE 16.49 | Forward PE 25.51 | Enterprise Value 234955741980 | Price to Sales(TTM) 5.31 |
Enterprise Value 234955741980 | Price to Sales(TTM) 5.31 | ||
Enterprise Value to Revenue 5.45 | Enterprise Value to EBITDA 20.31 | Shares Outstanding 1740460032 | Shares Floating 1730225115 |
Shares Outstanding 1740460032 | Shares Floating 1730225115 | ||
Percent Insiders 0.54 | Percent Institutions 80.83 |
Upturn AI SWOT
Abbott Laboratories
Company Overview
History and Background
Founded in 1888 by Wallace Abbott, Abbott Laboratories started as a small pharmacy. It has evolved into a global healthcare leader through organic growth and strategic acquisitions, focusing on pharmaceuticals, diagnostics, nutrition, and medical devices.
Core Business Areas
- Diagnostics: Provides a broad range of diagnostic systems and tests for hospitals, labs, and point-of-care settings. Key areas include immunoassay, clinical chemistry, hematology, and molecular diagnostics.
- Medical Devices: Develops and manufactures medical devices for cardiovascular care, neuromodulation, and diabetes care, including pacemakers, stents, glucose monitoring systems, and continuous glucose monitors (CGM).
- Nutrition: Offers a range of nutritional products for infants, children, and adults, including Similac infant formula, Ensure adult nutrition shakes, and Pediasure for children.
- Pharmaceuticals (Established Pharmaceuticals): Focuses on branded generic pharmaceuticals sold outside the U.S. These products address various therapeutic areas, including cardiovascular, metabolic, pain, and women's health.
Leadership and Structure
Robert B. Ford serves as Chairman and Chief Executive Officer. The company operates with a divisional structure, with each division led by a senior executive. The Board of Directors provides oversight and strategic guidance.
Top Products and Market Share
Key Offerings
- Similac: Infant formula brand. Competes with Nestle's Gerber, Mead Johnson's Enfamil. Revenue details are not disclosable, but Similac holds a significant market share in the infant formula segment. Market share fluctuates.
- Ensure: Adult nutrition shakes and drinks for seniors and those with dietary restrictions. Competitors include Nestle's Boost and various store-brand equivalents. While specific market share data varies by region, Ensure maintains a leadership position in the adult nutrition market.
- Number of Users: Millions Globally
- FreeStyle Libre: Continuous glucose monitoring (CGM) system. Competitors include Dexcom and Medtronic. FreeStyle Libre has captured a significant share of the CGM market due to its affordability and ease of use. 2023 global sales for FreeStyle Libre were $5.5 billion.
- Number of Users: Millions Globally
- Alinity: A family of diagnostic instruments, is used in blood screening, point of care, immunoassay, clinical chemistry, hematology and molecular diagnostics. Alinity competes with Siemens Healthineers, Roche, and Beckman Coulter. Market share details for Alinity are integrated in Abbott's broader diagnostics numbers
- Number of Users: Thousands of hospitals and labs
Market Dynamics
Industry Overview
The healthcare industry is characterized by innovation, regulation, and increasing demand driven by aging populations and rising healthcare costs. Key trends include personalized medicine, digital health, and value-based care.
Positioning
Abbott Laboratories is a diversified healthcare company with a strong global presence and a broad portfolio of products. Its competitive advantages include its R&D capabilities, brand recognition, and distribution network.
Total Addressable Market (TAM)
The global healthcare market is estimated to be worth trillions of dollars. Abbott is positioned to capture significant market share across its diagnostics, medical devices, nutrition, and pharmaceutical segments. Total TAM estimation is highly variable depending on the specific market segment.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Strong global presence
- Robust R&D capabilities
- Established brand reputation
- Strong financial performance
Weaknesses
- Exposure to regulatory risks
- Reliance on key products
- Competition from larger players
- Price pressures in generic pharmaceuticals
Opportunities
- Expansion into emerging markets
- Development of innovative products
- Acquisitions of complementary businesses
- Partnerships with healthcare providers
- Growth in digital health technologies
Threats
- Increased competition
- Patent expirations
- Economic downturns
- Changing healthcare regulations
- Product recalls
Competitors and Market Share
Key Competitors
- JNJ
- TMO
- DHR
- BDX
- SYK
- BSX
Competitive Landscape
Abbott competes with a range of large and specialized healthcare companies. Its diversified product portfolio and global presence provide a competitive advantage.
Major Acquisitions
Walk Vascular, LLC
- Year: 2018
- Acquisition Price (USD millions): 0
- Strategic Rationale: Enhances Abbott's portfolio of peripheral vascular devices.
Alere
- Year: 2017
- Acquisition Price (USD millions): 5300
- Strategic Rationale: Expanded Abbott's diagnostics business, adding point-of-care testing capabilities.
Growth Trajectory and Initiatives
Historical Growth: Abbott has experienced consistent growth driven by organic sales growth and strategic acquisitions.
Future Projections: Analysts expect Abbott to continue to grow at a steady pace, driven by new product launches, expansion into emerging markets, and growth in its core business segments.
Recent Initiatives: Recent initiatives include the launch of new diagnostic tests, expansion of its medical device portfolio, and investments in digital health technologies.
Summary
Abbott Laboratories demonstrates a robust and diversified healthcare profile with strong revenue streams, driven by key products and strategic acquisitions. Its well-balanced strengths position it for continued growth, though it must navigate competitive pressures and regulatory risks. Diversification and strategic innovation, alongside its global reach, provide a stable outlook. Continuous adaptation to the dynamic healthcare landscape is key.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Abbott Laboratories Investor Relations
- SEC Filings (10-K, 10-Q)
- Yahoo Finance
- Company Press Releases
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data and analyst estimates are subject to change. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abbott Laboratories
Exchange NYSE | Headquaters North Chicago, IL, United States | ||
IPO Launch date 1978-01-13 | Chairman of the Board, President & CEO Mr. Robert B. Ford | ||
Sector Healthcare | Industry Medical Devices | Full time employees 114000 | Website https://www.abbott.com |
Full time employees 114000 | Website https://www.abbott.com | ||
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.